<?xml version='1.0' encoding='utf-8'?>
<document id="24494031"><sentence text="Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment."><entity charOffset="27-35" id="DDI-PubMed.24494031.s1.e0" text="ONC1-13B" /></sentence><sentence text="Recently new drugs targeting androgen-dependent axis have been approved for the treatment of castration-resistant prostate cancer (CRPC) - Zytiga and Xtandi (formerly MDV3100), several other candidates (for example, ARN-509) are in early phases of clinical trials"><entity charOffset="29-37" id="DDI-PubMed.24494031.s2.e0" text="androgen" /></sentence><sentence text=" However despite significant improvement in overall survival with new treatments it is evident that resistance to these drugs develops" /><sentence text=" One of the approaches to overcome it is combination therapy and from this point of view some potential for drug-drug interactions can limit the application of the drug" /><sentence text=" We describe here the preclinical development of ONC1-13B, antagonist of androgen receptor, with similar to MDV3100 and ARN-509 mechanism of action"><entity charOffset="73-81" id="DDI-PubMed.24494031.s5.e0" text="androgen" /></sentence><sentence text=" It efficiently inhibits DHT-stimulated PSA expression and proliferation of prostate cancer cells, prevents binding of androgens to the AR ligand-binding domain, androgen-stimulated AR nuclear translocation and coactivator complex formation" /><sentence text=" In the LnCaP-Z2 xenograft model of prostate cancer ONC1-13B inhibits tumor growth and suppresses PSA expression" /><sentence text=" The in vivo activity of ONC1-13B is comparable to that of MDV3100 at similar doses, and even higher, calculated per unit of concentration in plasma" /><sentence text=" Distribution of ONC1-13B to the brain is less than that shown for MDV3100 and ARN-509, decreasing the risk of GABA-related seizure development"><entity charOffset="111-115" id="DDI-PubMed.24494031.s9.e0" text="GABA" /></sentence><sentence text=" Additionally ONC1-13B induces significantly lower in vitro CYP3A activity than for example MDV3100 (known strong CYP3A inducer) or ARN-509 and could be well suited for co-therapy with drugs that are known CYP3A substrates" /><sentence text=" Thus ONC1-13B is a new promising antiandrogen demonstrating high efficacy in a preclinical model of prostate cancer, with lower potential for seizures and drug-drug interaction"><entity charOffset="6-14" id="DDI-PubMed.24494031.s11.e0" text="ONC1-13B" /></sentence><sentence text=" " /></document>